

Universal Biosensors

Investor Presentation

FY 2024 – Annual Results

26/02/2025



Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

Important Disclaimer

Presentation and Company

You must read the following notices (Disclaimer) before reading or making any use of this presentation or any information contained in it (collectively, the Presentation). The Presentation is private and confidential and has been prepared solely for informational purposes by Universal Biosensors, Inc. (Company). By receiving the Presentation, you acknowledge that you have read, understood, accepted and satisfied the terms and conditions of this Disclaimer and agree to be bound by the terms and conditions of the Disclaimer, including any modifications to them. No part of this Presentation may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of the Company. This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person. Neither the Company, nor its officers or advisors or any other person warrants the accuracy of the analysis herein or guarantees the investment performance of the Company. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes.

Forward Looking Statements and Risks

The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of the United States Exchange Act. Forward-looking statements in this presentation include statements regarding our expectations, beliefs, hopes, intentions or strategies. You can identify these forward-looking statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “should”, “can”, “could”, “propose”, “potential”, “outlook”, “future”, “illustration”, “predict”, “will”, “would”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. All forward-looking statements included in this presentation are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. Factors that could cause actual results to differ materially from our current expectations include but are not limited to: the success of research and development activities, decisions by regulatory authorities regarding approval of our products, UBI’s ability to protect its patents and other intellectual property, difficulties or delays in manufacturing, the ability to successfully market new and existing products, competitive developments affecting our products, fluctuations in interest and currency exchange rates, distribution, pricing, reimbursement, acquisitions or divestitures, litigation or government investigations and legislation or regulations that affect product production. The Company is subject to a number of risks which may result in our actual results differing materially from our current expectations. These risks may be out of the control of, and unknown to, UBI and its officers, employees, advisors or agents. For a summary of key risks, refer to the Company’s most recent Form 10-K filed with the United States Securities and Exchange Commission and the Australian Securities Exchange.

Past Performance and Financial Information

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. Actual results could differ materially from those referred to in this Presentation. All dollar values are in Australian dollars (AUD\$) unless otherwise stated. This Presentation contains pro forma and forecast financial information. The pro forma and forecast financial information provided in the Presentation is for information purposes only and is not represented as an indication of the Company’s actual or future financial position. In addition, certain figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Therefore, the actual calculation of these figures may differ from the figures set out in the Presentation.

Photographs, Diagrams and Industry Data

Photographs in this Presentation which do not have descriptions are used for illustration only and should not be interpreted to mean that any person shown endorses this Presentation or its contents or that the assets shown are owned by the Company. Diagrams in this Presentation have been prepared by the Company, are illustrative only and may not be drawn to scale. Unless stated otherwise, all data contained in tables, charts and graphs is based on information available at the date of this Presentation. This Presentation contains industry and market data and statistics, third party estimates and other information (including industry forecasts and projections). The Company has not independently verified the industry data included in this Presentation.

Securities and Distribution Limited

Under applicable United States securities laws all of the shares of our common stock are “restricted securities” as that term is defined in Rule 144 under the Securities Act of 1933, as amended. Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders. Distribution or release of this Presentation outside Australia may be restricted by law and such restrictions should be observed. Persons who come into possession of this Presentation who are not in Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.



Universal Biosensors

Presentation Content

UBI Background

Achievements & Challenges

2024 Financial Performance

Business Focus for 2025

New Technology Focus for 2025

Appendix – Market Opportunities



Universal Biosensors

Background

Universal Biosensors (ASX:UBI) is a world leader in electrochemical cell technology that develops handheld, high performance liquid testing products in different market segments.

Our strategy is to develop and commercialise innovative, high precision, portable, liquid testing devices that are simple and convenient to use and provide immediate onsite results. Disrupting old practices of taking samples of analytes of interest, sending to an offsite laboratory and waiting many days to receive the results. Whilst our heritage will always remain in human health, our focus has shifted into large markets with much lower regulatory hurdles like wine and water. Significant investment has already been made in the development of the next range of products focused on heavy metals in water.

UBI products deliver analytical results with:

- simplicity and convenience,
- laboratory grade accuracy,
- a fraction of the time laboratory tests take,
- savings that are material to the customer,
- a much lower carbon footprint.

UBI are currently in 3 key markets:

1. **Blood testing:** Xprecia® product line for monitoring coagulation PT/INR.
2. **Wine testing:** Sentia® wine analyzer which monitors 6 key analytes throughout the wine production process.
3. **Veterinary testing:** Petrackr® which monitors blood glucose for cats and dogs which have diabetes.

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

Universal Biosensors

Background

Nine market leading products have been launched around the world in the last four years.

UBI's technology has been used to deliver more than **15 billion tests¹** to patients and customers worldwide.

Two more products are scheduled for launch in H1 2025. They will be the first two in a suite of environmental tests focused on heavy metals and impurities in water.

- **AQUASCOUT™** is a **world first** for the accurate, point of use measurement of lead and copper with a handheld device.



Prototype AQUASCOUT system

Achievements & Challenges so far



Achievements & Challenges

Blood Testing - Xprecia

Achievements

- ✓ FDA 510(k) and CLIA Waiver approval for Xprecia Prime in the US with first sales recorded.
- ✓ Signed US distribution partners NDC Inc and Henry Schein.
- ✓ Building global distribution capacity with 12 new distribution deals in US, Europe, Thailand and Chile.
- ✓ Regulatory approval for Xprecia Prime in US, UK, India, Australia, Singapore, Uruguay and Thailand.
- ✓ Year on year revenue growth of 10%.

Challenges

- New product launch of Xprecia Prime (best in class) device into US market.
- Building distribution and logistics support to facilitate sales in the US.
- Implementing middleware to connect to hospital software systems that allows seamless management of patient data.
- Converting customers that are using an existing device.



Achievements & Challenges

Wine Testing - Sentia

Achievements

- ✓ H2 strip revenue growth of 29% half on half globally.
- ✓ Annual test strips usage for wineries that have had Sentia for more than 12 months up 32%.
- ✓ 5 new distribution agreements signed with 10+ in the pipeline.
- ✓ Continuous improvement of the performance of all Sentia products.
- ✓ 35% strip sales growth and 15% device growth, half on half in US. 9% of wineries in the US are using Sentia.
- ✓ 25% of wineries in Australia are using Sentia.
- ✓ 17% of wineries in Canada are using Sentia.
- ✓ 9% of wineries in New Zealand are using Sentia.

Challenges

- Sentia is a **world first** disruptive technology. Momentum is building.
- During H1, there was an issue with the performance of our Free SO₂ test strips which related to the artificial intelligence (AI) algorithm embedded in the device. This materially impacted Q2 sales momentum as effected product was replaced Free of Charge. The issue has been resolved and sales momentum restored (Q3 test strip sales were largest on record for UBI, volume and revenue).
- Fragmented European market and a small sales team.

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.



Achievements & Challenges

Veterinary Testing - Petrackr

Achievements


- ✓ Established e-commerce platform and internal UBI systems to support direct to consumer sales initially in the North American market with expansion into Europe and ANZ to follow.
- ✓ New consumer packaging developed.
- ✓ Digital marketing strategy developed and a new execution partner in US appointed.
- ✓ Sales agreements signed with Amazon and Chewy.

Challenges

- Refocused sales strategy onto direct to consumer and ecommerce channels.
- Move away from distributors and veterinary practices as the primary focus.








2024 Financial Performance



2024 Financials

UBI Consolidated Results



Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.




2024 Financials


Blood Testing - Xprecia




Xprecia Revenue




Devices in Market



Test Strip Revenue*



Test Strips Sold*



Placing the universal power of biosensors into the hands of those who need it


*2022 test strip sales and volumes excluding Siemens sales

2024 Financials


Wine Testing - Sentia



Sentia Revenue




Devices in Market




Note: Revenue is down year on year due to issue with the performance of our Free SO₂ test strips which halted Q2 sales momentum but has been subsequently rectified.

Test Strip Revenue



Test Strips Sold



Placing the universal power of biosensors into the hands of those who need it


©Copyright Universal Biosensors 2025.

2024 Financials


Veterinary Testing - Petrackr



Petrackr Revenue




Devices in Market




Note: The number of devices in market has grown 31% year on year.

UBI has moved away from larger stocking orders to distributors and veterinary practices as they have not been able to sell product as expected.

Test Strip Revenue



Test Strips Sold



UBI has shifted direct-to-consumer focused channels such as Amazon and Chewy, Shopify and others, where the majority of the products are purchased online.

Test strip volumes and revenue are down year on year as UBI implemented the sales infrastructure to facilitate the shift to direct-to-consumer sales which we believe will be a more successful business model.

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

Business Focus for 2025



2025

Blood Testing – Xprecia

Focus on expansion of business in USA

- Win new business via Hospital Tenders and in CLIA Waiver clinics.
- Complete integration of Xprecia Prime with middleware needed to support connectivity to hospital data management systems (expected completion date April 2025).
- Capitalise on the newly appointed sales team and distribution partners (NDC and Henry Schein) to win business.
- Ongoing negotiations with new distribution partners committed to selling Xprecia Prime.

Maintain and grow European business via distribution network

- Build on existing distribution network of 37 partners across Europe.
- Focus on driving tender wins in existing markets.
- Ongoing negotiations with counterparties regarding a pan European distribution deal.

Rest of World

Focus on roll out of Xprecia Prime in:

- Australia using existing distribution network.
- South Africa using new distribution network.
- India using existing distribution network.
- Chile using existing distribution network. -



Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

2025

Wine Testing – Sentia

Increased focus on North America and Australia, New Zealand and other New World regions

- Increase focus on direct customer engagement
- Increase focus on attendance at industry conferences which has resulted in excellent results in H2 24.
- Increase focus on select “premium” distribution partners who are successfully selling Sentia.
- Move away from underperforming distribution partners.
- Aggressively drive analyser sales to gain market share.
- Increase focus on reaching targeted customer strip usage earlier.
- Reduce overall investment spending in Europe but:
 - ✓ Increase focus on targeted regions within Europe.
 - ✓ Increase focus on Central and Eastern Europe as they are quicker and more willing to adopt innovative technology.



2025

Veterinary Testing – Petrackr

Concentrate resources on USA market

- Launch e-commerce business in Q1 25.
- Support online retailers Amazon and Chewy.
- Expand online retail partnerships.
- Increase focus on fewer but better performing distribution partners.
- Increase focus to online marketing campaigns and direct-to-consumer activity.



Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

2025

HRL



HRL is a significant strategic asset given its unique service offering.

HRL is needed for calibrating Universal Biosensors' blood testing strip lots (Xprecia products) in accordance with global regulatory guidelines for point of care PT/INR products.

To complement this internal requirement for HRL's services HRL provides a variety of external blood-based testing services which generate additional revenue for UBI.

The external focus for HRL for 2025 is:

- Re-engagement of prior customers to facilitate new business for upcoming clinical trials.
- More focused management and engagement with current customers to facilitate new business.
- Increased targeted identification and contacting of potential new business.

2025

Cashflow

The board is committed to securing the future of UBI by:

1. Commercialising the world class, world first technology of UBI and to leverage our existing infrastructure to drive sales and margins,
2. Maintaining discipline around cost control,
3. Exploring funding options including:
 - Licensing arrangements and distribution deals for environmental products (AQUASCOUT), our blood product (Xprecia) and our wine platform technology (Sentia)
 - Leverage US corporate structure to source new funding opportunities,
 - Strategic investors,
 - Strategic acquisition,
 - Structured funding lines,
 - Other.

New Technology Focus for 2025



New Technology

AQUASCOUT

Universal Biosensors have developed a handheld water testing platform, AQUASCOUT, which can detect and monitor heavy metals in water samples.

AQUASCOUT™ addresses key issues associated with the current methods for heavy metal detection (laboratory testing) which are time consuming and expensive.

The potential market opportunities for AQUASCOUT include:

- Utilities (drinking water) lead pipe inventory and replacement.
- Mining, utilities and industrial waste monitoring.
- Utilities (drinking water/water treatment/recycling) water quality compliance testing.
- Consumers accessing the technology to test the quality of their water at home.

In the USA, the market size of these opportunities is estimated at \$2.68 billion p.a. (169 million tests)¹ (excluding the consumer testing market).

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

Source:
1. US EPA



New Technology

AQUASCOUT

The initial application of AQUASCOUT will be the testing of Lead and Copper in drinking water.

It is estimated that more than **13 million houses**¹ in the USA have lead service lines/pipes (10% of all houses) that need removal and replacement.

But to find those 13 million homes, **34 million** homes have been identified as unknown in terms of having lead infrastructure. All will have to be tested.

Recent US Government order has mandated the removal of all lead service lines / pipes in the US by 2033. Some water industry commentators estimate the cost to achieve this could be up to AUD \$75 billion².

Current methods for lead service line detection are time consuming, expensive and no accurate handheld detection product exists.

AQUASCOUT allows for cost effective, quick (minutes), low carbon footprint and onsite identification and location of levels of lead in drinking water and pipe infrastructure.

Field trials with US and UK utilities are to commence in March.

Commercial launch of Lead and Copper tests expected during H1 25.

Market	Market Size (AUD million)	Number of Tests (million)
Utilities (drinking water) - Lead/Copper inventory / line replacement	\$1,839	116
Mining waste	\$692	43
Utilities and Industrial (wastewater)	\$123	8
Utilities (drinking water) – Compliance Testing	\$16	1
Utilities (water treatment/recycling)	\$10	1
Total	\$2,680	169



New Technology

Other

UBI continues to develop and is making progress on:

Environmental sensors

- UBI's ambition is for the AQUASCOUT platform to support up to 6 products.
- Development work continues for other heavy metals sensors to be included on the platform including Zinc and Chromium.

Oncology biosensors

- UBI continues to make progress on biosensors to monitor prostate and colon cancer.
- UBI is undertaking a proof-of-concept project with a leading US University to develop a biosensor for nonalcoholic fatty liver disease.

Zero and Low Alcohol sensors

- UBI is undertaking a proof-of-concept project with a multinational beverage company to develop a "Zero" alcohol sensor.

Universal Biosensors

Corporate - Overview

Capital Structure

ASX Ticker	UBI
Share Price (at 24 FEB 25) \$AUD	\$0.07
Shares on Issue (m)	298.1
Options & Performance Rights (m)	113.8m
Market Capitalisation (\$AUD m)	\$21.2
Cash (at 31 DEC 24) (\$AUD m)	\$8.90
Top 20 Shareholders	65%

Share Price



Board/Management

Graham McLean	Craig Coleman	Judith Smith	David Hoey	John Sharman	Peter Mullin
Non-Executive Chairman	Non-Executive Director	Non-Executive Director	Non-Executive Director	Managing Director	Executive Director
<ul style="list-style-type: none"> Experienced senior executive in the medical technology industry in Australia, Asia and US, most recently with Stryker Corporation ("Stryker") as President Asia Pacific from 2017 to 2020. Director Suicide Prevention Australia and CleanSpace Holdings (ASX:CSX). 	<ul style="list-style-type: none"> Experienced investment and funds management executive. Executive Chairman of Viburnum Funds, an Australian-based specialist investment manager. Director 3PLearning (ASX:3PL), Sports Entertainment Group (ASX:SEG) and former director of Bell Financial Group (ASX:BFG). 	<ul style="list-style-type: none"> Highly experienced investment and funds management executive. Former Head of Private Equity at IFM Investors, a global fund manager. Director Acorn Capital Investment (ASX:ACQ). 	<ul style="list-style-type: none"> More than 30 years experience of executive-level experience in business development, licensing, strategic planning and financing for technology companies. Current president and CEO of Vaxxas, Inc. 	<ul style="list-style-type: none"> Extensive international business experience as Managing Director (MD) and Chief Executive Officer of ASX-listed companies and private equity businesses. Former CEO of Medical Developments International (ASX:MVP), Cyclopharm, Ltd, and private equity. 	<ul style="list-style-type: none"> A global strategic leader with a track record of success across a very diverse range of industries including in highly regulated environments, ASX listed businesses and family offices. Former CEO of The Comfort Group and Managing Director Pensions & Investments at ANZ (ASX:ANZ).

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

Note: All calculations are estimated and AUD m = million

Appendix - Market Opportunities



Market & Potential

Blood Testing

UBI Sales Potential

Installed Base Devices	Strips per Device p.a.	Strips Sold	Devices Sold	Strip Rev (A\$)	Device Rev (\$A)	Total Rev (A\$)
5,000	400	2,000,000	5,000	\$6.0m	\$2.5m	\$8.5m
	600	3,000,000	5,000	\$9.0m	\$2.5m	\$11.5m
	800	4,000,000	5,000	\$12.0m	\$2.5m	\$14.5m
	1,000	5,000,000	5,000	\$15.0m	\$2.5m	\$17.5m
10,000	400	4,000,000	5,000	\$12.0m	\$2.5m	\$14.5m
	600	6,000,000	5,000	\$18.0m	\$2.5m	\$20.5m
	800	8,000,000	5,000	\$24.0m	\$2.5m	\$26.5m
	1,000	10,000,000	5,000	\$30.0m	\$2.5m	\$32.5m
20,000	400	8,000,000	10,000	\$24.0m	\$5.0m	\$29.0m
	600	12,000,000	10,000	\$36.0m	\$5.0m	\$41.0m
	800	16,000,000	10,000	\$38.0m	\$5.0m	\$53.0m
	1,000	20,000,000	10,000	\$60.0m	\$5.0m	\$65.0m
30,000	400	12,000,000	10,000	\$36.0m	\$5.0m	\$41.0m
	600	18,000,000	10,000	\$54.0m	\$5.0m	\$59.0m
	800	24,000,000	10,000	\$72.0m	\$5.0m	\$77.0m
	1,000	30,000,000	10,000	\$90.0m	\$5.0m	\$95.0m

UBI revenue ambition

This market had been decreasing with the introduction of new anticoagulant drugs. However, it has stabilised in the last 3 years. Warfarin will not be completely replaced as treatment for certain conditions as the new drugs are not suitable for some applications.

This market is low growth, however still very lucrative for UBI. Our major competitor dominates the market with over 80% market share globally. UBI can disrupt this market as our clinical performance is superior and we have additional usability functions which improve the patient experience.



Market & Potential

Wine Testing

Global Wine Testing Market

	ANZ	USA	RoW	Total	ANZ	USA	RoW	Total
	Number of tests (m)	Number of tests (m)	Number of tests (m)	Number of tests (m)	Revenue (\$m)	Revenue (\$m)	Revenue (\$m)	Revenue (\$m)
Free SO ₂	1.62	7.00	35.07	43.69	\$5.6	\$35.0	\$114.3	\$154.9
Malic Acid	0.92	4.00	20.04	24.96	\$6.4	\$29.7	\$102.2	\$138.3
Glucose	0.69	3.00	15.03	18.72	\$2.4	\$8.5	\$32.6	\$43.6
Fructose	0.69	3.00	15.03	18.72	\$3.1	\$17.1	\$54.4	\$74.6
Titrateable Acidity	0.69	3.00	15.03	18.72	\$2.0	\$21.4	\$87.1	\$110.6
Acetic Acid	1.62	7.00	35.07	43.69	\$9.7	\$49.9	\$203.4	\$263.1
Total Tests	6.23	27.00	135.27	168.50	\$29.4	\$161.8	\$594.1	\$785.4
Total Devices	2,311	10,000	50,100	62,411	\$5.1	\$31.4	\$159.7	\$196.2
Total Revenue					\$34.5	\$193.2	\$753.8	\$981.7

UBI Sales Potential

Installed Base Devices	Market Share ¹	Strips per Device p.a.	Strips Sold	Devices Sold ²	Strip Rev (A\$) ³	Device Rev (A\$) ⁴	Total Rev (A\$)
2,500	0.74%	500	1,250,000	2,500	\$5.0m	\$5.6m	\$10.6m
	1.48%	1,000	2,500,000	2,500	\$10.0m	\$5.6m	\$15.6m
	2.97%	2,000	5,000,000	2,500	\$20.0m	\$5.6m	\$25.6m
	7.42%	5,000	12,500,000	2,500	\$50.0m	\$5.6m	\$55.6m
5,000	1.48%	500	2,500,000	2,500	\$10.0m	\$5.6m	\$15.6m
	2.97%	1,000	5,000,000	2,500	\$20.0m	\$5.6m	\$25.6m
	5.93%	2,000	10,000,000	2,500	\$40.0m	\$5.6m	\$45.6m
	14.84%	5,000	25,000,000	2,500	\$100.0m	\$5.6m	\$105.6m
10,000	2.97%	500	5,000,000	5,000	\$20.0m	\$11.3m	\$31.3m
	5.93%	1,000	10,000,000	5,000	\$40.0m	\$11.3m	\$41.3m
	11.87%	2,000	20,000,000	5,000	\$80.0m	\$11.3m	\$91.3m
	29.67%	5,000	50,000,000	5,000	\$200.0m	\$11.3m	\$211.3m
20,000	5.93%	500	10,000,000	10,000	\$40.0m	\$22.5m	\$62.5m
	11.87%	1,000	20,000,000	10,000	\$80.0m	\$22.5m	\$102.5m
	23.74%	2,000	40,000,000	10,000	\$160.0m	\$22.5m	\$282.5m
	59.35%	5,000	100,000,000	10,000	\$400.0m	\$22.5m	\$422.5m

The global wine testing market contains 6 main test types; Free SO₂, Malic Acid, Glucose, Fructose, Titrateable Acidity and Acetic Acid.

These are tested at different stages throughout the wine making process with Free SO₂ being the only test performed all throughout the year.

Based on market research and feedback it is estimated that a medium sized winery would perform 1,500 tests per year across these 6 testing parameters.

From customer data UBI have seen that customers performing more than 1,500 tests per year have taken approximately 3 years to reach this annual usage.

Continuous improvements of the tests on Sentia and market education around the benefits of Sentia are key to reaching these usage rates per device.

UBI revenue ambition



Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

All calculations are estimated and AUD


ANZ: Australia & New Zealand, RoW: Rest of World

Source: Australian and New Zealand Wine Industry Directory, New Zealand Winegrowers Annual Report, OIV Statistical Report on World Vitiviniculture, UBI Winemaker Interviews

Market & Potential

Veterinary Testing

Global Veterinary Blood Glucose Testing Market



UBI Sales Potential

Installed Base Devices	Market Share ¹	Strips Sold ²	Devices Sold ³	Strips Rev (\$A) ⁴	Device Rev (\$A) ⁵	Total Rev (\$A)
25,000	2.31%	3,125,000	25,000	\$3.1m	\$1.7m	\$4.8m
75,000	6.94%	9,375,000	50,000	\$9.3m	\$3.5m	\$12.8m
125,000	11.57%	15,625,000	62,500	\$15.6m	\$4.4m	\$20.0m
175,000	16.20%	21,875,000	87,500	\$21.8m	\$6.2m	\$28.0m

Major growth factors include:

- Increasing trend of pet adoption across the world.
- Owners are more concerned about their pet's health.
- Increased use of pet insurance to allow for diagnostics
- Obesity in pets is increasing worldwide. 56% of dogs were recorded as obese in US in 2017. Obesity is correlated to diabetes development.

Testing at home by pet parents accounts for over 70% of the market.



UBI long term revenue ambition

Placing the universal power of biosensors into the hands of those who need it

©Copyright Universal Biosensors 2025.

All calculations are estimated and AUD
Source: Global Companion Animal Blood Glucose Monitoring Industry Market Research Report 2020; Maia Research

END

John Sharman

Managing Director

jsharman@universalbiosensors.com